Novo Nordisk A/S $NVO Shares Sold by Beacon Investment Advisory Services Inc.

Key Points

• Beacon Investment Advisory Services Inc. reduced its holdings in Novo Nordisk A/S by 27.7% during Q2, now possessing 193,163 shares valued at approximately $13.33 million.
• Novo Nordisk A/S reported $0.97 EPS for the quarter, exceeding analyst estimates of $0.93, with a revenue of $11.69 billion.
• The company announced a semi-annual dividend of $0.4119 per share, resulting in a yield of 240.0% and a payout ratio of 22.53%.

Beacon Investment Advisory Services Inc. lowered its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 27.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 193,163 shares of the company's stock after selling 73,904 shares during the period. Beacon Investment Advisory Services Inc.'s holdings in Novo Nordisk A/S were worth $13,332,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Copeland Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares in the last quarter. North Capital Inc. purchased a new stake in shares of Novo Nordisk A/S in the first quarter valued at $27,000. Park Square Financial Group LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at $29,000. Stone House Investment Management LLC purchased a new stake in shares of Novo Nordisk A/S in the first quarter valued at $30,000. Finally, Disciplina Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock valued at $33,000 after purchasing an additional 297 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Down 1.3%

Novo Nordisk A/S stock opened at $58.78 on Thursday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The company has a market capitalization of $262.47 billion, a price-to-earnings ratio of 16.15, a PEG ratio of 2.26 and a beta of 0.66. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $127.61. The company's fifty day moving average price is $56.39 and its two-hundred day moving average price is $64.84.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.93 by $0.04. The firm had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. On average, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were given a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio is presently 22.53%.

Analyst Ratings Changes

A number of research firms have recently issued reports on NVO. BNP Paribas upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a report on Wednesday, August 13th. Zacks Research downgraded shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research note on Wednesday, August 20th. Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a "neutral" rating to a "buy" rating in a research note on Tuesday, September 16th. Rothschild Redb raised shares of Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 16th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of "Hold" and an average target price of $81.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.